Imugene Limited Price Chart
Imugene Limited IMU.XA Financial and Trading Overview
| Imugene Limited stock price | 0.06 AUD |
| Previous Close | 0.1 AUD |
| Open | 0.1 AUD |
| Bid | 0.09 AUD x N/A |
| Ask | 0.1 AUD x N/A |
| Day's Range | 0.1 - 0.11 AUD |
| 52 Week Range | 0.09 - 0.32 AUD |
| Volume | 6M AUD |
| Avg. Volume | 4.85M AUD |
| Market Cap | N/A |
| Beta (5Y Monthly) | 2.372413 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.005 AUD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
IMU.XA Valuation Measures
| Enterprise Value | 496.51M AUD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 2.975 |
| Enterprise Value/Revenue | 39.92 |
| Enterprise Value/EBITDA | -13.034 |
Trading Information
Imugene Limited Stock Price History
| Beta (5Y Monthly) | 2.372413 |
| 52-Week Change | -32.14% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.32 AUD |
| 52 Week Low | 0.09 AUD |
| 50-Day Moving Average | 0.12 AUD |
| 200-Day Moving Average | 0.16 AUD |
IMU.XA Share Statistics
| Avg. Volume (3 month) | 4.85M AUD |
| Avg. Daily Volume (10-Days) | 6.84M AUD |
| Shares Outstanding | N/A |
| Float | 5.18B |
| Short Ratio | N/A |
| % Held by Insiders | 15.40% |
| % Held by Institutions | 9.09% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | June 30, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -324.55% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -13.56% |
| Return on Equity (ttm) | -22.51% |
Income Statement
| Revenue (ttm) | 12.44M AUD |
| Revenue Per Share (ttm) | 0.002 AUD |
| Quarterly Revenue Growth (yoy) | -10.00000000000000000000000000000000% |
| Gross Profit (ttm) | 12.97M AUD |
| EBITDA | -38093488 AUD |
| Net Income Avi to Common (ttm) | -40429508 AUD |
| Diluted EPS (ttm) | -0.005 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 161.91M AUD |
| Total Cash Per Share (mrq) | 0.03 AUD |
| Total Debt (mrq) | 187.56K AUD |
| Total Debt/Equity (mrq) | 0.09 AUD |
| Current Ratio (mrq) | 48.547 |
| Book Value Per Share (mrq) | 0.032 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -41540920 AUD |
| Levered Free Cash Flow (ttm) | -34366272 AUD |
Profile of Imugene Limited
| Country | Australia |
| State | NSW |
| City | Sydney |
| Address | 4-6 Bligh Street |
| ZIP | 2000 |
| Phone | N/A |
| Website | https://www.imugene.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | N/A |
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.
Q&A For Imugene Limited Stock
What is a current IMU.XA stock price?
Imugene Limited IMU.XA stock price today per share is 0.06 AUD.
How to purchase Imugene Limited stock?
You can buy IMU.XA shares on the Cboe AU exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Imugene Limited?
The stock symbol or ticker of Imugene Limited is IMU.XA.
How many shares does Imugene Limited have in circulation?
The max supply of Imugene Limited shares is 0.
What is Imugene Limited Price to Earnings Ratio (PE Ratio)?
Imugene Limited PE Ratio is now.
What was Imugene Limited earnings per share over the trailing 12 months (TTM)?
Imugene Limited EPS is -0.005 AUD over the trailing 12 months.